Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 13/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13240077 | 0.97 | GHSR (0.49) | GHSRADRB3ADRB2ADRB1EPHX1 | |
| Trifluoroacetic Acid SCHEMBL2950710 | 0.91 | IDH1 (0.41) | ADRB3 | |
| Trifluoroacetic Acid SCHEMBL2949757 | 0.91 | KCNQ3 (0.44) | ADRB3ADRB2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL2944666 | 0.89 | RORC (0.40) | ADRB3 | |
| Trifluoroacetic Acid SCHEMBL2949058 | 0.88 | HTR6 (0.39) | ADRB3ADRB2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL2943606 | 0.88 | HTR6 (0.39) | ADRB3 | |
| Trifluoroacetic Acid SCHEMBL2945849 | 0.88 | ADRB3 (0.42) | ADRB3ADRB2ADRB1 | |
| SCHEMBL13240078 | 0.88 | HTR6 (0.42) | GHSRADRB3 | |
| Trifluoroacetic Acid SCHEMBL4618142 | 0.88 | HTR6 (0.39) | ADRB3 | |
| SCHEMBL13240081 | 0.88 | KCNQ3 (0.43) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754756-B2 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| EP-1943220-A2 | NOVEL INDOLE-CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | Boehringer Ingelheim International GmbH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| WO-2007048841-A2 | NOVEL INDOLE-CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | GHSR 314/4885ADRB3 2/4885ADRB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.